Trial Profile
A Phase 1, Prospective, Multi-center, Open-label Study to Assess the Plasma Pharmacokinetics and Lung Penetration of Intravenous (IV) Ceftolozane/Tazobactam in Critically Ill Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Ceftolozane/tazobactam (Primary)
- Indications Nosocomial pneumonia
- Focus Pharmacokinetics
- Sponsors Cubist Pharmaceuticals
- 24 Mar 2020 Results published in the Journal of Antimicrobial Chemotherapy
- 24 Apr 2018 Results evaluating lung penetration presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases
- 08 Oct 2017 Results presented at the IDWeek 2017